Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.
BPC density (BPCD)
ET density (ETD)
Endogenous testosterone (ET)
Low-risk prostate cancer
PSA density (PSAD)
Percentage of biopsy positive cores (BPC)
Prostate cancer
Prostate-specific antigen (PSA)
Radical prostatectomy
Tumor upgrading
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
25
05
2021
accepted:
28
09
2021
pubmed:
23
10
2021
medline:
17
2
2022
entrez:
22
10
2021
Statut:
ppublish
Résumé
To evaluate preoperative endogenous testosterone (ET) density (ETD), defined as the ratio of ET on prostate volume, and tumor upgrading risk in low-risk prostate cancer (PCa). From November 2014 to December 2019, 172 low-risk patients had ET (nmol/L) measured. ETD, prostate-specific antigen density (PSAD) and the ratio of percentage of biopsy positive cores (BPC) to prostate volume (PV), defined as BPC density (BPCD), were evaluated. Associations with tumor upgrading in the surgical specimen were assessed by statistical methods. Overall, 121 patients (70.3%) had tumor upgrading, which was predicted by BPCD (odds ratio, OR = 4.640; 95% CI 1.903-11.316; p = 0.001; overall accuracy: 70.3%). On multivariate analysis, tumor upgrading and clinical density factors related to each other for BPCD being predicted by ETD (regression coefficient, b = 0.032; 95% CI 0.021-0.043; p < 0.0001), PSAD (b = 1.962; 95% CI 1.067-2.586; p < 0.0001) and tumor upgrading (b = 0.259; 95% CI 0.112-0.406; p = 0.001). According to the model, as BPCD increased, ETD and PSAD increased, but the increase was higher for upgraded cases who showed either higher tumor load but significantly lower mean levels of either ET or PSA. As ETD increased, higher tumor loads were assessed; however, in upgraded patients, lower ET was also detected. ETD might stratify low-risk disease for tumor upgrading features.
Identifiants
pubmed: 34677784
doi: 10.1007/s11255-021-03008-0
pii: 10.1007/s11255-021-03008-0
pmc: PMC8599336
doi:
Substances chimiques
Testosterone
3XMK78S47O
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2505-2515Informations de copyright
© 2021. The Author(s).
Références
World J Urol. 2020 Apr;38(4):957-964
pubmed: 31154465
Prostate. 2019 Sep;79(13):1523-1529
pubmed: 31269285
J Urol. 2020 Oct;204(4):741-747
pubmed: 32898975
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):382-7
pubmed: 26439747
Aging Clin Exp Res. 2021 May;33(5):1399-1401
pubmed: 32557331
BMC Urol. 2019 Oct 17;19(1):94
pubmed: 31623595
J Clin Endocrinol Metab. 2009 Mar;94(3):907-13
pubmed: 19088162
Tumori. 2018 Mar-Apr;104(2):111-115
pubmed: 27791231
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):244-51
pubmed: 25841621
Urol Oncol. 2015 May;33(5):201.e1-8
pubmed: 25791753
World J Urol. 2021 Jul;39(7):2499-2506
pubmed: 33048258
Sci Rep. 2020 May 7;10(1):7722
pubmed: 32382097
J Urol. 2019 Dec;202(6):1188-1198
pubmed: 31347953
Curr Urol. 2017 Aug;10(3):118-125
pubmed: 28878593
Transl Androl Urol. 2017 Jun;6(3):566-579
pubmed: 28725600
Urol Int. 2017;99(2):215-221
pubmed: 28245478
Urol Oncol. 2015 Jul;33(7):329.e13-9
pubmed: 25960411
Eur Urol. 2009 Feb;55(2):310-20
pubmed: 18838208
J Natl Compr Canc Netw. 2018 May;16(5S):620-623
pubmed: 29784740
Int Urol Nephrol. 2019 Dec;51(12):2169-2180
pubmed: 31444696
World J Urol. 2020 Oct;38(10):2555-2561
pubmed: 31907633
Asian J Androl. 2016 Jul-Aug;18(4):639-43
pubmed: 26732103
Urol Int. 2017;98(1):32-39
pubmed: 27798942
Urology. 2014 Jan;83(1):28-32
pubmed: 24269219
Int Braz J Urol. 2018 Mar-Apr;44(3):440-451
pubmed: 29368876
Urol Oncol. 2016 Nov;34(11):482.e1-482.e4
pubmed: 27423822
Urol Int. 2019;102(1):43-50
pubmed: 30408799
Minerva Urol Nefrol. 2020 Feb;72(1):66-71
pubmed: 30298710
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Prostate. 2019 Jul;79(10):1125-1132
pubmed: 31045265
Urol Int. 2019;103(1):25-32
pubmed: 31067558
Tumori. 2017 Sep 18;103(5):464-474
pubmed: 28623636
Urol Int. 2017;99(2):207-214
pubmed: 28245480
Clin Genitourin Cancer. 2018 Aug;16(4):281-287
pubmed: 29550198
J Urol. 2015 Feb;193(2):403-13
pubmed: 25260832
Minerva Urol Nefrol. 2019 Apr;71(2):136-145
pubmed: 30767495
Int Urol Nephrol. 2021 May;53(5):843-854
pubmed: 33389506